<DOC>
	<DOC>NCT00514371</DOC>
	<brief_summary>This is a phase 2/3, open label trial for patients with relapsed-refractory multiple myeloma. Study agent is tanespimycin (KOS-953), at three different dose levels in combination with a fixed dose of bortezomib.</brief_summary>
	<brief_title>A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma</brief_title>
	<detailed_description>Phase 2/3 combination study comparing bortezomib plus one of three doses of tanespimycin in patients with relapsed-refractory multiple myeloma after failure of at least three prior anti-cancer therapy regimens. Prior therapy must include bortezomib and lenalidomide. Primary objective is to assess the dose-response relationship of objective response rate (ORR) using EBMT/IBMTR criteria of any three dose levels of tanespimycin (KOS-953) in combination with bortezomib after four treatment cycles.</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Good performance status Histologic evidence of multiple myeloma Have had at least three prior treatment regimens for multiple myeloma that included both bortezomib and lenalidomide No prior treatment with a heat shock 90 inhibitor or an investigational proteasome inhibitor No known infections of HAV, HBV, HCV, or HIV No chemotherapy, radiation therapy, or immune therapy for three weeks prior to enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Heat Shock Protein 90</keyword>
	<keyword>Hsp90</keyword>
	<keyword>KOS-953</keyword>
	<keyword>17-AAG</keyword>
	<keyword>bortezomib</keyword>
	<keyword>relapsed-refractory</keyword>
	<keyword>tanespimycin</keyword>
</DOC>